75 related articles for article (PubMed ID: 22975728)
21. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
Huang SM; Harari PM
Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
[TBL] [Abstract][Full Text] [Related]
22. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
[TBL] [Abstract][Full Text] [Related]
23. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
24. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC.
Krause M; Schütze C; Petersen C; Pimentel N; Hessel F; Harstrick A; Baumann M
Radiother Oncol; 2005 Feb; 74(2):109-15. PubMed ID: 15734198
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Karashima T; Sweeney P; Slaton JW; Kim SJ; Kedar D; Izawa JI; Fan Z; Pettaway C; Hicklin DJ; Shuin T; Dinney CP
Clin Cancer Res; 2002 May; 8(5):1253-64. PubMed ID: 12006546
[TBL] [Abstract][Full Text] [Related]
27. Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor.
Pangburn HA; Ahnen DJ; Rice PL
Cancer Prev Res (Phila); 2010 Apr; 3(4):560-72. PubMed ID: 20332299
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice.
Overholser JP; Prewett MC; Hooper AT; Waksal HW; Hicklin DJ
Cancer; 2000 Jul; 89(1):74-82. PubMed ID: 10897003
[TBL] [Abstract][Full Text] [Related]
29. A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2.
Szymanska M; Fosdahl AM; Nikolaysen F; Pedersen MW; Grandal MM; Stang E; Bertelsen V
J Cell Mol Med; 2016 Oct; 20(10):1999-2011. PubMed ID: 27469139
[TBL] [Abstract][Full Text] [Related]
30. Cetuximab/C225-induced intracellular trafficking of epidermal growth factor receptor.
Liao HJ; Carpenter G
Cancer Res; 2009 Aug; 69(15):6179-83. PubMed ID: 19602593
[TBL] [Abstract][Full Text] [Related]
31. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis.
Bhattacharyya S; Bhattacharya R; Curley S; McNiven MA; Mukherjee P
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14541-6. PubMed ID: 20679244
[TBL] [Abstract][Full Text] [Related]
32. High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.
Ha KD; Bidlingmaier SM; Zhang Y; Su Y; Liu B
Mol Cell Proteomics; 2014 Dec; 13(12):3320-31. PubMed ID: 25149096
[TBL] [Abstract][Full Text] [Related]
33. Anti-EGFR biparatopic-SEED antibody has enhanced combination-activity in a single molecule.
Kelton C; Wesolowski JS; Soloviev M; Schweickhardt R; Fischer D; Kurosawa E; McKenna SD; Gross AW
Arch Biochem Biophys; 2012 Oct; 526(2):219-25. PubMed ID: 22426455
[TBL] [Abstract][Full Text] [Related]
34. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis.
Takahashi JI; Nakamura S; Onuma I; Zhou Y; Yokoyama S; Sakurai H
Sci Rep; 2022 Jul; 12(1):11561. PubMed ID: 35798841
[TBL] [Abstract][Full Text] [Related]
35. A Cell-Based Internalization and Degradation Assay with an Activatable Fluorescence-Quencher Probe as a Tool for Functional Antibody Screening.
Li Y; Liu PC; Shen Y; Snavely MD; Hiraga K
J Biomol Screen; 2015 Aug; 20(7):869-75. PubMed ID: 26024945
[TBL] [Abstract][Full Text] [Related]
36. A Conjugate of an Anti-Epidermal Growth Factor Receptor (EGFR) VHH and a Cell-Penetrating Peptide Drives Receptor Internalization and Blocks EGFR Activation.
van Lith SAM; van den Brand D; Wallbrecher R; van Duijnhoven SMJ; Brock R; Leenders WPJ
Chembiochem; 2017 Dec; 18(24):2390-2394. PubMed ID: 28994180
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal Antibodies in Cancer--Fourth International Congress. EGFR/HER1 antibodies. 3-6 September 2004, Colorado Springs, CO, USA.
Zhu Z
IDrugs; 2004 Nov; 7(11):974-6. PubMed ID: 15551165
[No Abstract] [Full Text] [Related]
38. Lattice complex assembled by noncompetitive anti-EGFR antibodies regulates actin cytoskeletal reorganization.
Huang D; Lu T; Du X; Xi X; Zhang X; Zhang X; Zhang H; Sun F
Cancer Cell Int; 2020; 20():129. PubMed ID: 32336949
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of Macropinocytosis Processes in Glioblastomas May Be Exploited to Increase Intracellular Anti-Cancer Drug Levels: The Example of Temozolomide.
Colin M; Delporte C; Janky R; Lechon AS; Renard G; Van Antwerpen P; Maltese WA; Mathieu V
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30909495
[TBL] [Abstract][Full Text] [Related]
40. Leucine Zipper Downregulated in Cancer-1 Interacts with Clathrin Adaptors to Control Epidermal Growth Factor Receptor (EGFR) Internalization and Gefitinib Response in EGFR-Mutated Non-Small Cell Lung Cancer.
Huang HN; Hung PF; Chen YP; Lee CH
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
